IL237340A0 - Anxiolytic composition, formulation and method of use - Google Patents
Anxiolytic composition, formulation and method of useInfo
- Publication number
- IL237340A0 IL237340A0 IL237340A IL23734015A IL237340A0 IL 237340 A0 IL237340 A0 IL 237340A0 IL 237340 A IL237340 A IL 237340A IL 23734015 A IL23734015 A IL 23734015A IL 237340 A0 IL237340 A0 IL 237340A0
- Authority
- IL
- Israel
- Prior art keywords
- anxiety
- formulation
- preparation
- anxiety preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692380P | 2012-08-23 | 2012-08-23 | |
| PCT/US2013/056424 WO2014031975A1 (en) | 2012-08-23 | 2013-08-23 | Anxiolytic composition, formulation and method of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL237340A0 true IL237340A0 (en) | 2015-04-30 |
Family
ID=50148531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237340A IL237340A0 (en) | 2012-08-23 | 2015-02-22 | Anxiolytic composition, formulation and method of use |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20140057988A1 (enExample) |
| EP (2) | EP2887930A4 (enExample) |
| JP (2) | JP6722453B2 (enExample) |
| KR (1) | KR20150096370A (enExample) |
| CN (1) | CN104902883A (enExample) |
| AU (1) | AU2013305580A1 (enExample) |
| BR (1) | BR112015003796A2 (enExample) |
| IL (1) | IL237340A0 (enExample) |
| MX (1) | MX2015002378A (enExample) |
| SG (1) | SG11201501292UA (enExample) |
| WO (1) | WO2014031975A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014240102A1 (en) | 2013-03-15 | 2015-09-17 | Janssen Pharmaceutica Nv | Pharmaceutical composition of S-ketamine hydrochloride |
| NZ712270A (en) * | 2013-03-15 | 2020-02-28 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| MX370506B (es) | 2013-04-12 | 2019-12-16 | Icahn School Med Mount Sinai | Método para tratar trastorno de estrés post-traumático. |
| US9872841B2 (en) | 2013-09-13 | 2018-01-23 | National University Corporation Chiba University | Application of R-ketamine and salt thereof as pharmaceuticals |
| CA2957926A1 (en) | 2014-08-13 | 2016-02-18 | Janssen Pharmaceutica Nv | Method for the treatment of depression |
| JP6757537B2 (ja) * | 2014-08-29 | 2020-09-23 | 公益財団法人ヒューマンサイエンス振興財団 | 神経疾患モデル動物の製造方法及び神経疾患モデル動物 |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| EP3085366A1 (en) * | 2015-04-22 | 2016-10-26 | Institut du Cerveau et de la Moelle Epiniere-ICM | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| IL296380A (en) * | 2015-05-22 | 2022-11-01 | Vistagen Therapeutics Inc | Therapeutic uses of l-4-chlorokynurenine |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| CN105249531A (zh) * | 2015-08-06 | 2016-01-20 | 云南中烟工业有限责任公司 | 一种金丝楠木提取物的制备方法及其应用 |
| US9884057B2 (en) * | 2015-09-08 | 2018-02-06 | The Children's Hospital Of Philadelphia | Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome |
| EP3377050A4 (en) * | 2015-11-17 | 2019-11-20 | The Trustees of Columbia University in the City of New York | PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11622948B2 (en) | 2017-11-09 | 2023-04-11 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| WO2019094757A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| FR3075038B1 (fr) | 2017-12-15 | 2020-03-06 | Melchior Material And Life Science France | Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete |
| IL319020A (en) | 2017-12-22 | 2025-04-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| HUE058320T2 (hu) | 2017-12-29 | 2022-07-28 | Celon Pharma Sa | Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén |
| BR112020016500A2 (pt) | 2018-02-15 | 2020-12-15 | National University Corporation Chiba University | Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea |
| JP2021523228A (ja) | 2018-05-04 | 2021-09-02 | パーセプション ニューロサイエンス，インコーポレイティド | 物質乱用の治療方法 |
| WO2020041329A1 (en) * | 2018-08-20 | 2020-02-27 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| BR112021016404A2 (pt) | 2019-02-22 | 2021-10-13 | Harima Chemicals, Incorporated | Método de aplicação de material de brasagem sólido, método de produção de peça de trabalho revestida, aparelho de aplicação e material de brasagem sólido de perfil laminado |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| EP3968977A4 (en) * | 2019-05-15 | 2023-01-11 | The Trustees of Columbia University in the City of New York | COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS |
| EP4364812A3 (en) * | 2019-05-31 | 2024-09-04 | Afyx Development A/S | Intranasal administration of ketamine to cluster headache patients |
| PH12022551856A1 (en) | 2020-01-22 | 2024-01-03 | Seelos Therapeutics Inc | Reducing side effects of nmda antagonists |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5679714A (en) * | 1995-06-07 | 1997-10-21 | Weg; Stuart L. | Administration of ketamine for detoxification and treatment of tobacco addiction |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| US6391922B1 (en) * | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| EP1103256A1 (de) * | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| BRPI0809843A2 (pt) * | 2007-04-26 | 2014-09-23 | Auspex Pharmaceuticals Inc | "composto, composição farmacêutica e uso de um composto" |
| US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
-
2013
- 2013-08-23 US US13/975,060 patent/US20140057988A1/en not_active Abandoned
- 2013-08-23 BR BR112015003796A patent/BR112015003796A2/pt not_active IP Right Cessation
- 2013-08-23 EP EP13831683.1A patent/EP2887930A4/en not_active Ceased
- 2013-08-23 CN CN201380055487.7A patent/CN104902883A/zh active Pending
- 2013-08-23 WO PCT/US2013/056424 patent/WO2014031975A1/en not_active Ceased
- 2013-08-23 EP EP21156344.0A patent/EP3878442A1/en active Pending
- 2013-08-23 JP JP2015528691A patent/JP6722453B2/ja active Active
- 2013-08-23 MX MX2015002378A patent/MX2015002378A/es unknown
- 2013-08-23 AU AU2013305580A patent/AU2013305580A1/en not_active Abandoned
- 2013-08-23 SG SG11201501292UA patent/SG11201501292UA/en unknown
- 2013-08-23 KR KR1020157007330A patent/KR20150096370A/ko not_active Withdrawn
-
2015
- 2015-02-22 IL IL237340A patent/IL237340A0/en unknown
-
2017
- 2017-09-25 US US15/714,211 patent/US20180235906A1/en not_active Abandoned
-
2018
- 2018-06-29 JP JP2018124196A patent/JP6771512B2/ja active Active
-
2021
- 2021-08-02 US US17/391,808 patent/US20220160655A1/en not_active Abandoned
-
2024
- 2024-10-28 US US18/928,612 patent/US20250255834A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6771512B2 (ja) | 2020-10-21 |
| BR112015003796A2 (pt) | 2017-07-04 |
| US20250255834A1 (en) | 2025-08-14 |
| EP3878442A1 (en) | 2021-09-15 |
| JP2016501828A (ja) | 2016-01-21 |
| MX2015002378A (es) | 2015-09-25 |
| EP2887930A1 (en) | 2015-07-01 |
| US20180235906A1 (en) | 2018-08-23 |
| AU2013305580A1 (en) | 2015-04-09 |
| CN104902883A (zh) | 2015-09-09 |
| JP2018162302A (ja) | 2018-10-18 |
| KR20150096370A (ko) | 2015-08-24 |
| EP2887930A4 (en) | 2016-03-23 |
| SG11201501292UA (en) | 2015-05-28 |
| US20140057988A1 (en) | 2014-02-27 |
| US20220160655A1 (en) | 2022-05-26 |
| WO2014031975A1 (en) | 2014-02-27 |
| JP6722453B2 (ja) | 2020-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL237340A0 (en) | Anxiolytic composition, formulation and method of use | |
| KR101849656B9 (ko) | 디스플레이 장치의 제조방법, 디스플레이 장치의 제조장치 | |
| SI2858671T1 (sl) | Formulacija protiteles | |
| BR112015003354A8 (pt) | métodos e composições de microcápsula | |
| DK3777840T3 (da) | Rna-formulering til immunterapi | |
| FI20125229L (fi) | Menetelmä, laite ja järjestely ihmismäärän arvioimiseksi | |
| DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK2804587T3 (da) | Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed | |
| DK2872153T3 (da) | Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf | |
| BR112015003227A2 (pt) | processos de clicoconjugação e composições | |
| DK2900657T3 (da) | Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse | |
| DK2890397T3 (da) | Antiprolactinreceptor-antistofformulering | |
| CU24158B1 (es) | Método de obtención de 1-kestosa | |
| BR112014028282A2 (pt) | composição cosmética anidra e método cosmético | |
| LT2931313T (lt) | Genų inžinerijos būdu sukonstruotų antukūnų prieš il-23p19 tirpalo formuluotės | |
| EP2810070A4 (en) | EXTRACTION OF MYCOTOXINES | |
| EP2925338A4 (en) | LYOPHILIZED FORMULATION OF TAT-NR2B9C | |
| BR112014020677A2 (pt) | composições de farinha de milho e métodos de produção | |
| BR112015013025A2 (pt) | composição cosmética fotorreticulável, método de esmalte e conjunto | |
| PT2825039T (pt) | Formulação de ibuprofeno injetável | |
| BR112014017038A2 (pt) | método, e aparato | |
| BR112015007217A2 (pt) | compostos e usos do composto | |
| BR112015002542A2 (pt) | método de caracterização de um objeto | |
| BR112014032452A2 (pt) | aparelho ortodôntico e método de atuação de um aparelho ortodôntico | |
| EP2807256A4 (en) | MYONECTIN (CTRP15), COMPOSITION COMPRISING SAME AND METHODS OF USE |